Testing a supplement for weight management in adults with overweight or obesity
Tests a supplement against placebo for weight control in adults with overweight or obesity.
Key facts
- Who runs it
- Elenzia
- Where
- Redditch, United KingdomSee the site
- Trial code
- Registry title
- Weight and Metabolic Management Study
- Status
- Recruiting
- People taking part
- 200 people, planned
- Started
- 15 Sept 2026
- Expected to end
- Feb 2027
- Type of study
- Interventional, 4 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- elénzia CONTROL®
- Placebo
- Record updated
- 17 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 25 to 65 who either have never used GLP-1 weight-loss medicines or have recently stopped them. It tests a nutritional supplement against a placebo for 16 weeks.
- Age
- 25 to 65 years
- Sex
- All sexes can join.
- Disease stage
- People who have never used GLP-1 medicines need a BMI of 27 or more and under 40 kg/m². People who stopped GLP-1 medicines need a BMI under 40 kg/m², with no lower limit.
- Earlier treatment
- Two groups can join: people who never used GLP-1 receptor agonist medicines, and people who stopped them before enrolment. The second group must have been on a stable dose for at least 6 months and lost at least 10% of body weight before stopping.
Main reasons for not taking part
- Currently smoking or using nicotine products
- Pregnant or breastfeeding
- Type 1 or type 2 diabetes
- Current use of weight-loss, appetite or blood sugar supplements or medicines
- Taking part in another interventional trial now or in the last 30 days
The registry criteria, word for word
Show all 22 criteriaShow less
Who can take part
- Adults aged 25 to 65 years inclusive at the time of consent
- Participants must fall into one of the following cohorts:
- GLP-1-naïve cohort: individuals who have never used GLP-1 receptor agonist medications
- Post-GLP-1 cohort: individuals who have discontinued GLP-1 receptor agonist therapy, with the last injection taken prior to enrolment
- Body mass index (BMI), calculated using self-reported height and weight at screening:
- GLP-1-naïve cohort: BMI ≥27 kg/m² and <40 kg/m²
- Post-GLP-1 cohort: BMI <40 kg/m², with no lower BMI limit
- Participants entering the post-GLP-1 cohort must have been on a stable GLP-1 receptor agonist dose for at least 6 months and achieved at least 10% body-weight reduction prior to discontinuation
- Participants must be capable of providing informed consent independently and demonstrate understanding of the study requirements
- Participants must be willing and able to complete study procedures remotely through a mobile application, provide self-measured weight and waist circumference data, and take the allocated study capsules daily as instructed
- Participants must have access to a compatible smartphone, reliable internet access, and their own home weighing scale; Additional participant characteristics: A prior diagnosis of prediabetes, insulin resistance, or polycystic ovary syndrome (PCOS) may be self-reported at screening for study population characterisation and subgroup analyses. These conditions are not required for eligibility and do not determine inclusion in the study
Who cannot take part
- Previous or current use of elénzia CONTROL®
- Current use of anorexigenic medications, including sibutramine, bupropion for weight-loss indication, liraglutide, topiramate, orlistat, fluoxetine when used for appetite suppression, cannabinoids, medroxyprogesterone, megestrol, or systemic corticosteroids used as appetite stimulants
- Current participation in another interventional clinical trial, or participation in an interventional study within the previous 30 days
- Known hypersensitivity or allergy to any component of elénzia CONTROL® or the placebo, including citrus flavonoids, milk thistle extract, bitter melon extract, iodine, zinc, selenium or chromium
- Diagnosis of type 1 or type 2 diabetes mellitus
- History of significant endocrine disorders, including Cushing's disease or Addison's disease
- Chronic illnesses that may significantly affect food intake, weight regulation or metabolic status, including active malignancy, advanced liver disease, renal failure or acquired immunodeficiency syndrome (AIDS)
- Current use of herbal or other dietary supplements specifically intended for weight loss, appetite control, fat burning, or blood glucose regulation
- Current smoking or use of nicotine-containing products
- Pregnancy or breastfeeding
- Current use of insulin, sulfonylureas (e.g. gliclazide, glimepiride), warfarin, lithium, amiodarone, high-dose iodine supplements
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 25 and 65 years old?
Where in United Kingdom
- ElénziaRedditch, United KingdomContact: Godsfavour Oghifo, BPharm, MScTaking people
About the trial
What the trial wants to find out
The goal of this clinical trial is to learn whether elénzia CONTROL®, a nutritional supplement, can support weight management in adults who have either never used GLP-1 weight-loss medications or have recently stopped using them. The main question it aims to answer is:
Read full original descriptionShow less
Does taking elénzia CONTROL® for 16 weeks help reduce body weight in adults who have never used GLP-1 medications or help prevent weight regain in adults who have recently stopped using them?
The study will also look at changes in appetite, sugar cravings, mood, energy, diet, sleep, physical activity, stress, quality of life, and waist circumference.
Researchers will compare elénzia CONTROL® with a placebo (a look-alike supplement that does not contain the active ingredients) to see whether elénzia CONTROL® has an effect on weight management.
Participants will:
Take two capsules of elénzia CONTROL® or placebo once a day, 30 minutes before their largest meal, for 16 weeks.
Use a mobile app to record whether they have taken their capsules and complete study questionnaires and assessments.
Measure and report their body weight and waist circumference throughout the study.
The 4 groups in the trial
- GLP-1-Naïve - elénzia CONTROL®Treatment being tested
Participants who have never used GLP-1 receptor agonists will receive elénzia CONTROL® for 16 weeks.
Treatment: elénzia CONTROL®
- GLP-1-Naïve - PlaceboPlacebo, for comparison
Participants who have never used GLP-1 receptor agonists will receive placebo for 16 weeks.
Treatment: Placebo
- Post-GLP-1 - elénzia CONTROL®Treatment being tested
Participants who have recently discontinued GLP-1 receptor agonist therapy will receive elénzia CONTROL® for 16 weeks.
Treatment: elénzia CONTROL®
- Post-GLP-1 - PlaceboPlacebo, for comparison
Participants who have recently discontinued GLP-1 receptor agonist therapy will receive placebo for 16 weeks.
Treatment: Placebo
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Randomised, Double-Blind, Placebo-Controlled Trial Evaluating the Effects of elénzia CONTROL® on Weight and Metabolic Health in Adults Naïve to or Who Have Recently Discontinued Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Use
- Plain-language title
- Testing a supplement for weight management in adults with overweight or obesityGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 13 November 2026.
- Fit questions
- Built from NCT07789223, who can take part
- Record updated
- 17 September 2026